Tissue Collection for Studies of Lymph Cancer
- Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To develop these studies, researchers want to collect samples from people with cancer or precancer conditions of the lymph system. These conditions include multiple myeloma, different types of lymphoma, and adult leukemia/lymphoma. The samples collected will include blood, urine, bone marrow, and tumor and skin tissue.
- To collect tissue samples to study different types of lymph cancer.
- Individuals at least 18 years of age who have a lymphoid cancer or precancer condition.
- Participants will be screened with a physical exam and medical history.
- Different samples will be collected for study. Blood samples will be collected at the initial testing. More blood samples will be collected at different treatment points. Other liquid samples include urine, bone marrow, and any abnormal fluid. Tumor tissue and skin tissue biopsies will also be collected for study.
- Treatment will not be provided as part of this study.
Leukemia-Lymphoma, Adult T-Cell
|Study Design:||Time Perspective: Prospective|
|Official Title:||Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol|
- Sample Acquisition [ Time Frame: Open ] [ Designated as safety issue: No ]
- Comparative analysis of normal and tumor tissue [ Time Frame: 10 years ] [ Designated as safety issue: No ]
- Development of new therapeutic targets using molecular profiling. [ Time Frame: 10 years ] [ Designated as safety issue: No ]
|Study Start Date:||August 2012|
An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory investigations conducted in the Metabolism Branch, including analysis of cellular, molecular, genetic and genomic biology are attempting to develop new prognostic and diagnostic models, therapeutic agents and novel treatment approaches for lymphoid malignancies and premalignant conditions.
This biology protocol is designed to allow sample acquisition for use in the study of lymphoid malignancies and malignancy precursors, including but not limited to B and T cell malignancies, such as diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL). A variety of laboratory investigations will be conducted on blood, tumor, bone marrow, urine, abnormal fluid and normal tissue, including analysis of cellular, molecular, genetic and genomic biology in the support of NIH translational trials to develop new therapeutic agents and novel treatment approaches as well as new prognostic and diagnostic models.
Adult patients with confirmed pathological diagnosis of lymphoid malignancy or lymphoid precursor, including B-cell and T-cell lymphomas: including but not limited to diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL).
The purpose of this study is to examine, in an exploratory fashion, a variety of biologic assays relevant to the investigation of lymphoid malignancies.
It is anticipated that up to 60 consented subjects, 50 at the NCI site, 10 at the UWI site, will be studied each year. Thus, an accrual ceiling of 600 consented subjects is planned over 10 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01676805
|Contact: Margaret Shovlin, R.N.||(301) firstname.lastname@example.org|
|Contact: Wyndham H Wilson, M.D.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|University of the West Indies||Recruiting|
|Principal Investigator:||Wyndham H Wilson, M.D.||National Cancer Institute (NCI)|